[Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
Minushkin
O N
ON
Maslovskiĭ
L V
LV
Anikina
N Iu
NIu
Shuleshova
A G
AG
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors*; D064750:Rabeprazole; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D064750:Rabeprazole; D006180:Proton-Translocating ATPases; D009853:Omeprazole